hVIVO plc (AIM: HVO), a specialist contract research organisation (CRO) in infectious disease testing, has announced positive topline results from a Phase 2a Respiratory Syncytial Virus (RSV) human challenge trial for Enanta Pharmaceuticals' antiviral candidate EDP-323. This trial involved 142 healthy adult volunteers and demonstrated significant antiviral efficacy.
Participants were divided into three groups - high dose, low dose and placebo. Results indicated that EDP-323 achieved an 85-87% reduction in viral load as measured by qRT-PCR, a 97-98% reduction in infectious viral load via viral culture, and a 66-78% decrease in total clinical symptoms score, all with p-values less than 0.0001.
The successful outcomes underscore the value of human challenge trials in expediting efficacy data and mitigating risks in later-stage clinical development. With over 30 years of experience, hVIVO supports crucial research across various respiratory viruses, including RSV and COVID-19.
EDP-323, an oral antiviral, has received U.S. Food and Drug Administration (FDA) Fast Track designation.
Enanta's first RSV candidate, Zelicapavir (EDP-938), has also shown promising results in prior trials.
hVIVO operates from its state-of-the-art facilities in Canary Wharf, London, the world's largest commercial human challenge trial unit, equipped with advanced virology and immunology laboratories. The Group offers a comprehensive suite of early clinical development services, maintaining partnerships with four of the top ten global biopharma companies.
TC BioPharm plans Proof of Concept preclinical studies of TCB 008 for treatment of monkey pox
LakeShore Biopharma names new chief executive officer
SIFI's AKANTIOR receives European Commission approval
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation
RedHill Biopharma launches Talicia in UAE for H. pylori treatment
RedHill Biopharma reports promising results for opaganib in obesity and diabetes studies
Acurx Pharmaceuticals presents positive Ibezapolstat Phase 2 clinical trial results for CDI
Technavio predicts increase in global peptide therapeutics market size